Newsletter | August 4, 2025

08.04.25 -- From Extraterrestrial Life To Cancer Research: Engineering Breakthroughs

SPONSOR

Become part of CNS Summit, an exclusive community where passionate life sciences innovators and decision-makers unite around a shared commitment to collaboration. Our year-round programming includes global gatherings and virtual events, all leading to our flagship 4-day annual Summit in Boston November 2-5. Join executive leaders from across the entire life sciences ecosystem as we work together toward Collaborating for Novel Solutions.

FEATURED ARTICLE

From Extraterrestrial Life To Cancer Research: Engineering Breakthroughs

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has before, explains Delve Therapeutics cofounder and CTO Mike Flanagan, Ph.D.  

INDUSTRY INSIGHTS

The Science Behind Patient Decision Making In Clinical Trials

Clinical trial decisions are emotional, not purely rational. Behavioral science reveals how framing, trust, emotion, and design shape participation. Empathy and clarity drive better choices.

Developing Drugs For Rare Diseases: Generating Clinical Evidence

For rare diseases, scientific breakthroughs often stall before reaching patients. A new approach to generating clinical evidence could change that trajectory.

Securing A Treatment Through Grit And Collaboration

Discover how one family defied the odds—bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

Conduct Early-Phase Studies To Improve Manufacturability, Mitigate Risk

While clinical efficacy is the critical benchmark for any drug program, ensuring manufacturability is also vital. An experienced CDMO can help you establish efficient and cost-effective production strategies.

RWD And New Technologies Show Potential In Clinical Trial Recruitment

Learn how integrating RWD sources enables sponsors to understand where patients are receiving care, how they are being treated, and which sites have the capabilities to meet enrollment targets.